Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 29:14:1289885.
doi: 10.3389/fonc.2024.1289885. eCollection 2024.

Effects of surgical management for gastrointestinal stromal tumor patients with liver metastasis on survival outcomes

Affiliations

Effects of surgical management for gastrointestinal stromal tumor patients with liver metastasis on survival outcomes

Lei Liu et al. Front Oncol. .

Abstract

Purpose: To investigate the effect of surgical resection on survival in gastrointestinal stromal tumors synchronous liver metastasis (GIST-SLM) and to develop clinically usable predictive models for overall survival (OS) and cancer-specific survival (CSS) in patients.

Methods: We identified patients in the SEER database diagnosed with GISTs from 2010 to 2019. We used propensity score matching (PSM) to balance the bias between the Surgery and No surgery groups. Kaplan-Meier(K-M) analysis was used to detect differences in OS and CSS between the two groups. The nomogram to predict 1, 3, and 5-year OS and CSS were developed and evaluated.

Results: After PSM, 228 patients were included in this study. There were significant differences in 1, 3, and 5-year OS and CSS between the two groups (OS: 93.5% vs. 84.4%, 73.2% vs. 55.3%, 60.9% vs. 36.9%, P=0.014; CSS: 3.5% vs.86.2%,75.3% vs.57.9%, 62.6% vs. 42.9%, P=0.02). We also found that patients who received surgery combined with targeted therapy had better OS and CSS at 1, 3, and 5 years than those who received surgery only (OS: 96.6% vs.90.9%, 74.9% vs. 56.8%, 61.7% vs. 35.5%, P=0.022; CSS: 96.6% vs. 92.1%, 77.4% vs.59.2%,63.8% vs. 42.0%, P=0.023). The area under the curve (AUC) was 0.774, 0.737, and 0.741 for 1, 3, and 5-year OS, respectively, with 0.782 and 0.742 for 1, 3, and 5-year CSS. In the model, C-index was 0.703 for OS and 0.705 for CSS and showed good consistency.

Conclusion: Surgical treatment can improve the OS and CSS of patients with GIST-SLM. In addition, the combination with chemotherapy may be more favorable for the long-term survival of patients. Meanwhile, we constructed the nomograms for predicting OS and CSS at 1, 3, and 5-year, and validated them internally. Our model can contribute to clinical management and treatment strategy optimization.

Keywords: gastrointestinal stromal tumor; nomograms; surgery; survival; synchronous liver metastasis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Patient inclusion and exclusion flow chart.
Figure 2
Figure 2
Kaplan-Meier survival curves for OS and CSS between the surgery and no surgery groups; (A) Overall survival (OS). (B) Cancer-specific survival (CSS).
Figure 3
Figure 3
Kaplan-Meier survival curves for OS and CSS between the surgery and no surgery groups stratified by chemotherapy; (A) Overall survival (OS); (B) Cancer-specific survival (CSS).
Figure 4
Figure 4
Nomogram predicting the probabilities of survival. (A) Overall survival (OS); (B) Cancer-specific survival (CSS). * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001.
Figure 5
Figure 5
The receiver operating characteristic curve. (A) 1-year OS; (B) 3-year OS; (C) 5-year OS; (D) 1-year CSS; (E) 3-year CSS; (F) 5-year CSS.
Figure 6
Figure 6
The calibration curves. (A) 1-year OS; (B) 3-year OS; (C) 5-year OS; (D) 1-year CSS; (E) 3-year CSS; (F) 5-year CSS.
Figure 7
Figure 7
The decision curve analysis. (A) Overall survival (OS); (B) Cancer-specific survival (CSS).

Similar articles

Cited by

References

    1. Joensuu H, Hohenberger P, Corless CL. Gastrointestinal stromal tumour. Lancet (2013) 382:973–83. doi: 10.1016/S0140-6736(13)60106-3 - DOI - PubMed
    1. Joensuu H, Vehtari A, Riihimäki J, Nishida T, Steigen SE, Brabec P, et al. . Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol (2012) 13:265–74. doi: 10.1016/S1470-2045(11)70299-6 - DOI - PubMed
    1. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg (2000) 231:51–8. doi: 10.1097/00000658-200001000-00008 - DOI - PMC - PubMed
    1. Søreide K, Sandvik OM, Søreide JA, Giljaca V, Jureckova A, Bulusu VR. Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies. Cancer Epidemiol (2016) 40:39–46. doi: 10.1016/j.canep.2015.10.031 - DOI - PubMed
    1. Yang DY, Wang X, Yuan WJ, Chen ZH. Metastatic pattern and prognosis of gastrointestinal stromal tumor (GIST): a SEER-based analysis. Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex (2019) 21:1654–62. doi: 10.1007/s12094-019-02094-y - DOI - PubMed